NAUT · 10-Q · 2026Q1 · Full report
Product Launch and Transition
Nautilus Biotechnology, Inc. · 2026-04-28 · Importance 48 · Surprise 60
Nautilus launched an Iterative Mapping Early Access Program in January 2026 beginning with target-specific service offerings for the microtubule-associated protein tau ("Tau") and expects to extend the program to additional proteoforms and disease areas such as oncology over time. The company describes a phased commercialization plan: Early Access (company-performed analyses via its facility/cloud), a land-and-expand model, opening pre-orders in late 2026, instrument installations at customer sites beginning in early 2027, and general availability of Broadscale proteomics capabilities in the first half of 2027. At initial general availability Nautilus expects to offer the Voyager instrument, its Tau proteoform assay, and a second proteoform assay, with subsequent consumable releases to expand capabilities and performance. Management states it does not anticipate the early access activities will produce material revenue and will instead be used to generate data, publications and customer demand ahead of instrument and consumables sales.
Key facts
- Nautilus expects to initiate its commercial launch in late 2026 by opening the Nautilus Voyager platform for pre-orders.
- Nautilus expects instrument installations at customer sites beginning in early 2027.
- Nautilus anticipates general availability of Broadscale proteomics capabilities in the first half of 2027.
- At launch, Nautilus expects general availability to include the Voyager instrument, the Tau proteoform assay, and a second proteoform assay.
- Nautilus expects first generally available broadscale consumable kits are designed to deliver strong initial performance with subsequent releases expected to further expand capabilities and enable the platform to meet or exceed previously announced product specifications.
- Nautilus announced the launch of its Iterative Mapping Early Access Program in January 2026 starting with target specific service offerings for analysis of the microtubule-associated protein tau.
- Nautilus' Nautilus Voyager platform integrates nanofabricated protein arrays, affinity reagent probing, advanced optics and fluidics, and machine learning–based analysis into an end-to-end workflow inclusive of instrumentation, consumables, and software.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Nautilus expects to initiate its commercial launch in late 2026 by opening the Nautilus Voyager platform for pre-orders. |
| revenue | positive | probable | — | Nautilus expects instrument installations at customer sites beginning in early 2027. |
| revenue | positive | probable | — | Nautilus anticipates general availability of Broadscale proteomics capabilities in the first half of 2027. |
| revenue | positive | realized | — | Nautilus announced the launch of its Iterative Mapping Early Access Program in January 2026 starting with target specific service… |